34th week of 2008 patent applcation highlights part 44 |
Patent application number | Title | Published |
20080200444 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS - Disclosed are urea compounds of formula I, stereoisomer, or pharmaceutical acceptable salts thereof, and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetic-related diseases. | 2008-08-21 |
20080200445 | Heterocyclic aspartyl protease inhibitors -
Disclosed are compounds of the formula I
| 2008-08-21 |
20080200446 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof - The present invention provides compounds represented by the structural formula (I): | 2008-08-21 |
20080200447 | Neurotherapeutic Compositions and Method - Administration of β-Lactam compounds, including β-lactam antibiotics and β-lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidence inter alia by anxiolytic and anti-aggressive behavior modification and enhanced cognition. Therapeutic methods for using such compounds and their pharmaceutical formulations are described. | 2008-08-21 |
20080200448 | New Pyridine Analogues VIII 518 - The present invention relates to certain new pyridin analogues of Formula (I) | 2008-08-21 |
20080200449 | TREPROSTINIL ADMINISTRATION USING A METERED DOSE INHALER - Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil. | 2008-08-21 |
20080200450 | Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction - Use of ivabradine, or 3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-methyl}-(methyl)-amino]-propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one, its addition salts with a pharmaceutically acceptable acid and their hydrates, for obtaining a medicament intended for the treatment of endothelial dysfunction. | 2008-08-21 |
20080200451 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 - Compounds of the formula (I), in which W, R, R | 2008-08-21 |
20080200452 | Oral, Rapidly Disintegrating Film, Which Cannot be Spat Out, for a Neuroleptic - Film-form, single-layered, cavity-free preparation free of surfactants, effervescent additive and taste masker and comprising one or more film former(s), one or more gel former(s) and one or more active ingredient(s) from the group of neuroleptics. | 2008-08-21 |
20080200453 | Methods of treating metabolic syndrome using dopamine receptor agonists - The present invention is directed to a method of simultaneously treating hypertension, hypertriglyceridemia, a pro-inflammatory state, a pro-coagulative state, and insulin resistance (with or without treating obesity or endothelial dysfunction), associated with or independent from Metabolic Syndrome, as well as vascular disease such as cardiovascular, cerebrovascular, or peripheral vascular disease comprising the step of administering to a patient suffering from such disorders a therapeutically effective amount of a central acting dopamine agonist. In one embodiment, the central acting dopamine agonist is bromocriptine, optionally combined with a pharmaceutically acceptable carrier. | 2008-08-21 |
20080200454 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S - Carbon-linked tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis. | 2008-08-21 |
20080200455 | 1-Aryl- or 1-Alkylsulfonyl-Heterocyclylbenzazoles As 5-Hydroxytryptamine-6 Ligands - The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor. | 2008-08-21 |
20080200456 | Substituted 8-Heteroaryl Xanthines - The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A | 2008-08-21 |
20080200457 | 4-Cyclopropyl-1,2,3,-Thiadiazole Compound, Agrohorticultural Plant Disease Controlling Agent And Method Of Using The Same - The present invention relates to 1,2,3 -thiadiazole compounds represented by formula (I): | 2008-08-21 |
20080200458 | Methods and compositions for the treatment of body composition disorders - This invention relates to methods of treating, managing and preventing body composition disorders, and to compounds and pharmaceutical compositions useful in such methods. | 2008-08-21 |
20080200459 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS - The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: | 2008-08-21 |
20080200460 | Chemical Compounds - Compounds of formula (I): | 2008-08-21 |
20080200461 | MODULATORS OF ACETYL-COENZYME A CARBOXYLASE AND METHODS OF USE THEREOF - The present invention provides compounds of formula I: | 2008-08-21 |
20080200462 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS - Disclosed are new substituted pyrazole and triazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof: | 2008-08-21 |
20080200463 | Thiazole Derivatives and Use Thereof - The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries. | 2008-08-21 |
20080200464 | Substituted heterocycles and methods of use - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 2008-08-21 |
20080200465 | ANTIPATHOGENIC BENZAMIDE COMPOUNDS - The present invention is related to methods of treating viral and protozoan infections in mammals using antipathogenic benzamide compounds having the formula | 2008-08-21 |
20080200466 | Organic Compounds For the Treatment of Inflammatory or Allergic Conditions - Compounds of formula (I) in free or pharmaceutically acceptable salt form, where R | 2008-08-21 |
20080200467 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS - Disclosed are alpha keto amide and alpha hydroxy amide compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetic-related diseases. | 2008-08-21 |
20080200468 | 2-Substituted 5-Membered Heteroaryl Carboxylates as Hm74a Receptor Agonists - Therapeutically active heteroaryl carboxylic acid derivatives of Formula (I) wherein R | 2008-08-21 |
20080200469 | PHTHALAZINONE DERIVATIVES - Compounds of the formula (I): | 2008-08-21 |
20080200470 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity - The present invention relates to certain derivatives of cycloalkanediones invariably substituted with a chroman-2-yl, 2-quinolyl or —O-phenyl residue which are serotonin (5-hydroxytryptamine, 5-HT) 5-HT | 2008-08-21 |
20080200471 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY - The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): | 2008-08-21 |
20080200472 | Therapeutic agents useful for treating pain - A compound of formula: | 2008-08-21 |
20080200473 | Imidazo [1,2-a]Pyridine Compounds, Compositions, Uses and Methods Thereto - The present invention relates to novel imidazo[1,2-a]pyridine compounds of general formula (I): | 2008-08-21 |
20080200474 | NOVEL FLUNARIZINE SALT FORMS AND METHODS OF MAKING AND USING THE SAME - Disclosed herein are novel salts of flunarizine with improved properties. Also described herein are novel pharmaceutical compositions comprising such flunarizine salts, methods of making, and related methods of treatment. | 2008-08-21 |
20080200475 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors - Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: (I) wherein A | 2008-08-21 |
20080200476 | ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS - The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers. | 2008-08-21 |
20080200477 | Retinoid-Containing Compositions Having Reduced Irritation Effect - The present invention features a composition including (i) a retinoid, and (ii) an interleukin-8 inhibitor. The composition provides reduced irritation to human skin. | 2008-08-21 |
20080200478 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE - This invention comprises antineoplastic curcumin derivatives and methods of preparation and use thereof. Particular reference is made to the following isomeric compounds | 2008-08-21 |
20080200479 | Ocaperidone Salts and Pharmaceutical Compositions Containing the Same - The invention relates to new salts of ocaperidone and uses thereof, particularly in the pharmaceutical industry. The invention discloses specific salts of ocaperidone having increased water solubilities, as well as therapeutic methods by administering said salts, in particular for treating various diseases of the central or peripheral nervous system, especially central nervous system. It further deals with pharmaceutical compositions comprising said salts and methods for preparing the same. | 2008-08-21 |
20080200480 | Fungicidal 6-Phenyltriazolopyrimidinylamines - 6-Phenyltriazolopyrimidinylamines of the formula I, | 2008-08-21 |
20080200481 | Method of treatment of myocardial infarction - Myocardial infarction in a mammal is treated by administering to the mammal a therapeutically effective amount of a chemical Src family tyrosine kinase protein inhibitor and the use of such inhibitor compounds for the preparation of a medicament for treating myocardial infarction. Myocardial infarction can be prevented by administering to the mammal a prophylactic amount of the inhibitor. The inhibitor preferably is an inhibitor of Src protein selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof. The Src family tyrosine kinase inhibitors can be used to prepare medicaments for the treatment of myocardial infarction. Also disclosed are articles of manufacture containing a chemical Src family tyrosine kinase inhibitor. | 2008-08-21 |
20080200482 | Use of a Partially Neutralized, Anionic (Meth)Acrylate Copolymer as a Coating for the Production of a Medicament Releasing Active Substance at Reduced Ph Values - (EN) The invention relates to the use of a partially neutralized, anionic (meth)acrylate copolymer comprising radically polymerized units of 25 to 95 percent by weight of C | 2008-08-21 |
20080200483 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists - Compounds of formula I | 2008-08-21 |
20080200484 | Pharmaceutical Compositions Comprising A Multifunctional Phosphodiesterase Inhibitor and An Adenosine Uptake Inhibitor - The present invention relates to pharmaceutical compositions comprising at least one multifunctional phosphodiesterase inhibitor (MPDEI) and at least one adenosine uptake inhibitor. The present invention also relates to compositions comprising cilostazol and dipyridamole and their use. | 2008-08-21 |
20080200485 | Kinase Inhibitors - Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use, thereof. More particularly, disclosed are inhibitors of Aurora-2 (Aurora-A) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer. | 2008-08-21 |
20080200486 | Combination Of Organic Compounds - The invention provides a pharmaceutical combination comprising:
| 2008-08-21 |
20080200487 | Salts of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide - Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes. | 2008-08-21 |
20080200488 | Combinations Comprising a Protein Kinase Inhibitor Being a Pyrimidylaminobenzamide Compound and a Hsp90 Inhibitor Such as 17-Aag - The invention provides a pharmaceutical combination comprising:
| 2008-08-21 |
20080200489 | Combination of Organic Compounds - The invention provides a pharmaceutical combination comprising:
| 2008-08-21 |
20080200490 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists - This invention provides the compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R | 2008-08-21 |
20080200491 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel - The present invention relates to certain 1,2-dihydro-spiro[3H-indole-3,4′-piperidine]compounds of Formula (Ia): and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein G, R1, R2, R3, R4, R5, and Ar are as disclosed herein (“Compound(s) of the Invention”), which are useful, for example, as cardio-protective and/or neuro-protective agents. The invention also provides pharmaceutical compositions comprising a Compound of the Invention and methods for treating, preventing and/or managing a vascular, cardiovascular or neurological disease or disorder, comprising administering to a patient in need thereof a Compound of the Invention. | 2008-08-21 |
20080200492 | METHODS FOR THE TREATMENT OF ALCOHOL ABUSE, ADDICTION AND DEPENDENCY - The present invention is directed to methods for the treatment of alcohol abuse, addiction and/or dependency, alone and in combination with one or more anti-addiction agents. | 2008-08-21 |
20080200493 | Use of Oxycodone for Treating Visceral Pain - It is possible to effectively treat moderate to severe visceral pain by administering analgesic medications comprising the opioid oxycodone or pharmaceutically acceptable salts thereof. Visceral pain and especially acute (i.e. non-chronic) visceral pain can be effectively treated by administering oxycodone at a dosage which is lower than the corresponding dosage of other opioids like morphine. | 2008-08-21 |
20080200494 | Imidazopyridine Derivatives - The invention provides imidazopyridine derivatives represented by the general formula [I] [in which R | 2008-08-21 |
20080200495 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof - Pyrrolopyridine compounds corresponding to formula (I): | 2008-08-21 |
20080200496 | SUBSTITUTED 1H-PYRROLO[3,2-b, 3,2-c, and 2,3-c]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Ie - The present invention discloses and claims compounds of formula (I) | 2008-08-21 |
20080200497 | Hepatitis C Inhibitor Peptide Analogs - The compounds of formula I wherein R | 2008-08-21 |
20080200499 | Selective Insecticides and/or Acaricides Based on Substituted Cyclic Dicarbonyl Compounds and Safeners - The present invention relates to the use of selective insecticidal and/or acaricidal compositions, characterized in that they comprise an effective amount of an active compound combination comprising
| 2008-08-21 |
20080200500 | Quinoline Derivatives as Nk3 Antagonists - Compounds of Formula I | 2008-08-21 |
20080200501 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION - The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity). | 2008-08-21 |
20080200502 | METHODS OF LOWERING LIPID LEVELS IN A MAMMAL - This invention relates to methods for lowering lipid levels in mammals using compounds that inhibit advanced glycation endproducts (AGEs), LR-9, LR-74 and LR-90. These compounds, which inhibit non-enzymatic protein glycation, also inhibit the formation of advanced lipoxidation endproducts (ALES) on target proteins by trapping intermediates in glycoxidation and lopoxidation and inhibiting oxidation reactions important in the formation of AGEs and ALEs. | 2008-08-21 |
20080200503 | Macrocylic Inhibitors Of Hepatitis C Virus - Inhibitors of HCV of formula (I). | 2008-08-21 |
20080200504 | Amide Alkyl Pyridiyl Quinolines as Nk3 Receptor Modulators - Compounds of Formula (I) wherein R | 2008-08-21 |
20080200505 | Piperidines for the Treatment of Chemokine Mediated Diseases - The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state. | 2008-08-21 |
20080200506 | Oral Preparation of Dyclonine Hydrochloride - The present invention discloses an oral preparation of dyclonine hydrochloride for the endoscope examination in upper gastrointestinal tract, which has the effects of anaesthetization and lubrication, and especially an oral preparation comprising dyclonine hydrochloride that has the advantages of avoiding the foam in the body cavity, preventing vomit, and offering a clear view. The preparation of the present invention comprises, as main ingredients, 0.2%-3% weight percent of dyclonine hydrochloride, 1%-12% weight percent of polyvinyl alcohol, 1%-10% volume percent of glycerin, 1%-10% volume percent of a defoaming agent, and a balance of a pharmaceutically acceptable adjuvant. The viscosity of the preparation is in a range of 30 to 300 mpa·s and the pH value is in a range of 2.0 to 8.0. | 2008-08-21 |
20080200507 | Crystalline Non-Solvated Methanesulfonic Acid Salt of 1-(4-(2-Piperidinylethoxy)Phenoxy)-2-(3-Hydroxyphenyl)-6-Hydroxynaphthalene - The present invention relates to the mesylate salt of 1-(4-(2-piperidinylethoxy)phenoxy)-2-(3-hydroxyphenyl)-6-hydroxynaphthalene. | 2008-08-21 |
20080200508 | Pharmaceutical Compositions For Sleep Disorders - Pharmaceutical compositions are provided for the pharmacological treatment of breathing disorders and, more specifically, to compositions containing agents having serotonin receptor modulating activity for the alleviation of sleep apnea (central and obstructive) and other sleep-related breathing disorders wherein the active ingredients are released such as to extend effective blood plasma concentrations across the period of sleep. | 2008-08-21 |
20080200509 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS - The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. | 2008-08-21 |
20080200510 | Combination of Organic Compounds - The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof and comprising at least one CB1 antagonist, or a pharmaceutically acceptable salt thereof. | 2008-08-21 |
20080200511 | Novel Compounds and Methods of Using the Same - The present invention relates to novel compounds of Formula (I) wherein ‘X’ represents an amino acid group, ‘n’ is an integer between 1 and 4, ‘R | 2008-08-21 |
20080200512 | Hepatitis C virus polymerase inhibitors - The invention provides a compound of formula: | 2008-08-21 |
20080200513 | Pyridine N-Oxides As Antiviral Agents - The present invention relates to pyridinone derivatives of formula (I): | 2008-08-21 |
20080200514 | Indications for Direct Thrombin Inhibitors - The invention relates to new indications for direct thrombin inhibitors such as dabigatran etexilate in the CNS and other fields. | 2008-08-21 |
20080200515 | SOLID STATE FORMS OF ENANTIOPURE ILAPRAZOLE - The invention relates to solid state forms of enantiopure ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfnyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a solid form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders such as those discussed above. | 2008-08-21 |
20080200516 | SOLID STATE FORMS OF RACEMIC ILAPRAZOLE - The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-( | 2008-08-21 |
20080200517 | CRYSTALLINE FORMS OF SOLVATED ILAPRAZOLE - The invention relates to crystalline forms of various solvates of ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising crystalline ilaprazole hydrate according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders. | 2008-08-21 |
20080200518 | Substituted Cyclic Urea Derivatives - Certain novel phenyl substituted cyclic urea derivatives have unexpected insecticidal activity. These compounds are represented by formula I: where A, B a, D, b, E, G, c, d, J, X and R through R | 2008-08-21 |
20080200519 | TETRAHYDRONAPHTHALENYLAMIDES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS - The present invention relates to the compounds of formula I, | 2008-08-21 |
20080200520 | Iron Modulators - Iron modulator compounds of formula (I) are provided for treating amyloidoses wherein R | 2008-08-21 |
20080200521 | Novel hydroxamic acid containing amino acid derivatives - Novel hydroxamic acid containing amino acid derivatives are provided that are useful for treatment of inflammation, inflammatory and immunological diseases; lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; and for treatment or prophylaxis of metabolic disorders. | 2008-08-21 |
20080200522 | COMPOSITION AND METHOD FOR CONTROLLING HOUSE INSECT PEST - The present invention provides a composition for controlling a house insect pest, such as termites, ants or cockroaches, which comprises, as active ingredients, at least two compounds selected from the group consisting of (a) a certain pyridine compound, (b) a benzoylurea compound, (c) a pyrethroid compound and (d) a certain hydrazone compound; and a composition for controlling a house insect pest, which comprises, as an active ingredient, a certain hydrazone compound. | 2008-08-21 |
20080200523 | Derivatives of squaric acid with anti-proliferative activity - The present invention provides derivatives of squaric acid, in particular derivatives of 3,4-diamino-cyclobut-3-ene-1,2-dione and tautomers and isomers thereof, as a single stereoisomer or a mixture of stereoisomers, or as a pharmaceutically acceptable salt thereof. These compounds show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer. | 2008-08-21 |
20080200524 | Amide compounds as ion channel ligands and uses thereof - Compounds are disclosed that have a formula represented by the following: | 2008-08-21 |
20080200525 | PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES - Compounds of formula | 2008-08-21 |
20080200526 | Composition for the Prevention and Treatment of Allergic Inflammatory Disease - Disclosed herein is a composition for the treatment and prevention of allergic inflammatory diseases comprising N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or pharmaceutically acceptable salts. The composition exhibits excellent medicinal effects on allergic inflammatory diseases, with a great reduction in typical chronic inflammation symptoms, such as an increase of eosinophil level in bronchoalveolar lavage fluid, total leukocyte level and eosinophil level in blood, the hypertrophy or hyperplasia of bronchial epithelium due to an increase in the number of mucus cells, a reduction in alveolar surface area resulting from the hyptertrophy of alveolar walls, and the infiltration of inflammatory cells. | 2008-08-21 |
20080200527 | Cannabinoid Receptor Modulators - Compounds of formula (I), are cannabinoid CB1 receptors, useful, inter alia in the treatment of obesity: | 2008-08-21 |
20080200528 | Derivatives of a 1-Phenyltriazole - Compounds of formula (I) | 2008-08-21 |
20080200529 | Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels - This invention relates to novel 2-amino benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). | 2008-08-21 |
20080200530 | Diaryl and Arylheteroaryl Urea Derivatives as Modulators of 5-Ht2a Serotonin Receptor Useful for the Prophylaxis or Treatment of Progressive Multifocal Leukoencephalopathy - The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of progressive multifocal leukoencephalopathy. | 2008-08-21 |
20080200531 | CDKI pathway inhibitors as inhibitors of tumor cell growth - The invention provides new methods for inhibiting the CDKI pathway and specifically inhibiting tumor cell growth. The invention further provides new and specific inhibitors of tumor cell growth, as well as means for discovery of additional such inhibitors. The present inventors have surprisingly discovered that Cyclin-Dependent Kinase 3 (CDK3) is specifically required for tumor cell growth, in contrast to other members of the CDK family. | 2008-08-21 |
20080200532 | Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them - Provided are polymorphic forms of fluvastatin sodium and processes for their preparation. | 2008-08-21 |
20080200533 | Drug or Pharmaceutical Compounds and a Preparation Thereof - The administration of pharmaceuticals of drugs which are having less solubility, lower bioavailability, lower bioabsorbability, less rate of absorption has become a big challenge in day to day life. Therefore an attempt has been made to prepare a complex modified form of the said pharmaceutical or drug such that the modified complex drugs or pharmaceuticals exhibits the enhanced properties of solubility, bioavailability, bioabsorbability and rate of absorption despite the increased complexity of the molecule. Surprisingly such modification was found to enhance retentivity of the active drug ingredient in the blood. Higher amounts of the active drug ingredient has shown lower toxicity. | 2008-08-21 |
20080200534 | Cosmetic and Pharmaceutical Compositions Comprising Lauroyl Proline and an Ester of Anhydrohexitol and of an Aliphatic Carboxylic Acid - Composition (A) containing, for 100% of its mass: from 10 mass % to 90 mass % of N-lauroyl proline (I) and from 10 mass % to 90 mass % of an ester (II) of anhydrohexitol and of a saturated or unsaturated, linear or branched aliphatic carboxylic acid containing from 12 to 20 carbon atoms optionally substituted with one or more hydroxyl groups, or of a mixture of esters (II); use thereof for preparing a medicament with lipolytic activity, intended to induce slimming of the human or animal body and/or the reduction of cellulite or of the orange-feel appearance; cosmetic formulation or therapeutic composition containing same; process for the preparation thereof and process for the solubilization of N-lauroyl proline (I) in a liquid medium. | 2008-08-21 |
20080200535 | Amine Compounds - There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. | 2008-08-21 |
20080200536 | Pharmaceutical Formulation with High Stability and Dissolution and Manufacturing Process - Disclosed herein are a pharmaceutical formulation with high stability and dissolution, and a method for preparing the pharmaceutical formulation. The pharmaceutical formulation comprises a pharmacologically active substance, a solvent, a solubilizer, a surfactant, an antioxidant, and an adsorbent. According to the pharmaceutical formulation and the method, the pharmacologically active substance is mixed with the solvent, the solubilizer agent and the surfactant for improving the solubility of the pharmacologically active substance to obtain an amorphous liquid or semi-solid state, the antioxidant is melted together with the mixture to solve poor chemical stability of the pharmacologically active substance in an amorphous or liquid state, and the adsorbent is strongly adsorbed to the molten mixture so as to be transformed into a powder form so that the resulting molecules are reconstituted into very tiny crystal forms within the adsorbent to ensure chemical stability. | 2008-08-21 |
20080200537 | Antiestrogenic glyceollins suppress human breast and ovarian carcinoma proliferation and tumorigenesis - The flavonoid family of phytochemicals, particularly those derived from soy, has received attention regarding their hormonal activity and their effects on human health and disease. The types and amounts of these compounds in soy and other plants are controlled by both constitutive expression and stress-induced biosynthesis. The health benefits of soy may therefore be dependent upon the amounts of the various hormonally active phytochemicals present. We have identified increased biosynthesis of the isoflavonoid phytoalexin compounds, Glyceollins I, II and III, in soy plants grown under stressed conditions (elicited soy), which exhibit marked anti-estrogenic effects on ER function. Here we demonstrate that specific glyceollins, isolated from elicited soy, displayed anti-estrogenic activity, suppressing basal and estrogen stimulated colony formation of ER-positive estrogen dependent breast cancer cells and inhibiting ER-dependent gene expression of progesterone receptor (PgR) and stromal derived factor-1 (SDF1/CXCL12). Examining the effects of glyceollin on in vivo tumor formation/growth we demonstrate the ability of glyceollins to significantly suppress basal and estrogen-stimulated tumor growth of ER-positive MCF-7 breast and BG-1 ovarian carcinoma cells in ovariectomized female nude mice. We further demonstrate that the effects of glyceollins on suppression of tumor growth correlate with inhibition of estrogen stimulated PgR expression. In contrast to the uterotropic activity of tamoxifen the glyceollins displayed no uterine agonist activity. The Glyceollin (I-III) compounds may represent an important component of the health effects of soy as well as represent novel anti-estrogens useful in the prevention or treatment of breast and ovarian carcinoma. | 2008-08-21 |
20080200538 | Inhibition of Monocyte Survival, Differentiation, or Proliferation - Methods comprising administering to the subject apigenin, an apigenin derivative, apigenin and at least one apigenin derivative, or a combination of apigenin derivatives are provided for treating inflammation in a subject in need of the same. | 2008-08-21 |
20080200539 | Topical antifungal treatment - The present invention is a topical skin preparation for treatment of fungal infections of the skin and nails. The preparation comprises triacetin in combination with one or more antifungal agents. In a preferred form, the preparation comprises a combination of the antifungal agents tolnaftate and grisiofulvin are used in combination with triacetin. The concentrations of these constituents are 40 to 50% concentration triacetin, 30 to 50% acetone, 0.5-3.0% concentration tolnaftate and 0.5-4.0% concentration grisiofulvin, in one preferred embodiment. Other compounds, such as ethyl alcohol, acetone, amino acids such as n-acetylcysteine, and herbal additives may also be added to the preparation. Further, other antifungal agents such as nystatin, clortimazole, econazole, ketoconazole, miconazole, solconazole, oxiconizole, naftifine, terbinafine, and butenafine, for example, may be substituted for the antifungal agents tolnaftate and grisiofulvin. The preparation of the present invention is effective in treating immune compromised patients and those with diabetes, as well as relatively healthy persons. | 2008-08-21 |
20080200540 | ANTIPARASITIC AGENTS - The present invention relates to compounds of the formula (I) | 2008-08-21 |
20080200541 | Benzofuranyl Alkanamine Derivatives and Uses Thereof - Compounds of formula I or pharmaceutically acceptable salts thereof are provided: | 2008-08-21 |
20080200542 | Benzoyl-Substituted Serineamides - The present invention relates to benzoyl-substituted serineamides of the formula I | 2008-08-21 |
20080200543 | Immunomodulating Agent, Anti-Cancer Agent and Health Food Containing Monoacetyldiacylglycerol Derivatives - The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against cancer cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect apoptosis. Therefore, mono acetyl diacyl glycerol derivatives according to the present invention can be effectively used for an immunomodulating agent, a sepsis treatment, a cancer treatment, and a health food for an immune modulation or the prevention of cancer. | 2008-08-21 |
20080200544 | Oil agent and lubricant agent, moisturizer and external preparation composition containing the same - The present invention provides an oil agent having water solubility and oil solubility, as well as suppressed stickiness when applied to skin to exhibit excellent feeling of use, and also provides a lubricating agent, a moisturizing agent and an external preparation containing said oil agent. | 2008-08-21 |